Using Mycophenolate Mofetil for Gastrointestinal Issues in Children with Henoch-Schönlein Purpura

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of Mycophenolate Mofetil (MMF) in treating children aged 3 to 18 years who have refractory gastrointestinal symptoms associated with Henoch-Schönlein Purpura (HSP). HSP is a common vasculitis in children that can lead to severe gastrointestinal complications. The study aims to assess the clinical features of these patients and the outcomes of MMF treatment after they have not responded to corticosteroids. Participants will be monitored for improvements in their gastrointestinal symptoms and overall health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ages range from 3 to 18 years old;
2. Patients who meet the diagnostic criteria for HSP and involve the digestive tract: acute diffuse abdominal colic, including intussusception and gastrointestinal bleeding, appears during the course of the disease or is found on physical examination;
3. Refractory gastrointestinal type HSP: treated with Intravenous corticosteroid 2 mg/kg/d for 3 days without effecacy or relapsed during the attenuation of corticosteroid
4. Parents or guardians agree to treatment and sign a written informed consent form.

Exclusion Criteria:

1. Patients who are allergic to MMF;
2. Patients with severe diseases: such as systemic malignancies, heart failure, liver and renal failure, Immune deficiency, severe infectious diseases, organ transplant surgery, or other current indications for emergency surgery;
3. Patients with other digestive system diseases;
4. Those who have previously used MMF clinical trials;
5. Other situations the researcher thought inappropriate to participate in the study.

Where it's running

• Sun Yat-sen Memorial Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Weiping Tan, PhD — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Study coordinator: Haiyan Wang, MD
• Email: wanghy78@mail.sysu.edu.cn
• Phone: +8613560489257

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reduced immunosuppression for older kidney transplant recipients with TruGraf/TRAC monitoring

  This study will see if stopping mycophenolate mofetil (MMF) in kidney transplant patients aged 55 and older, while using TruGraf/TRAC blood tests to watch for rejection and infections, is as safe as continuing the medication.

  Recruiting at 3 sites Phase 4 Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT06568549

• Treatment strategies for severe Henoch-Schönlein Purpura in children

  This study tests whether giving children with severe Henoch-Schönlein Purpura either a steroid or an immune treatment helps them feel better and manage their stomach problems.

  Recruiting Children's Hospital of Fudan University · Shanghai and 2 other locations · NCT03647852

• Comparing treatments for isolated skin vasculitis

  This study is testing which of three common treatments—colchicine, dapsone, or azathioprine—works best for people with isolated skin vasculitis over a year.

  Recruiting at 7 sites Phase 2 University of Pennsylvania · Kansas City, Kansas and 15 other locations · NCT02939573

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.